Objective: To estimate the incidence, mortality and 5-year prevalence rates of liver cancer in 2008, China.
Methods: Data from both 36 cancer registries and the Third National Death Survey in China (2004 - 2005) were used to estimate the incidence, mortality and 5-year prevalence of liver cancer in 2008 in the country by using the mathematical models to predict the liver cancer incidence and mortality in the next 20 years.
Results: In 2008, the incident cases of liver cancer was 402 208 (14.3% of the total cancers) and the number of deaths from liver cancer was 372 079 (19.0% of the total cancers). The incidence rate was 25.7/100 000, ranking the third among all cancers. The mortality rate was 23.7/100 000, ranking the second among all the cancers. The 5-year prevalence of liver cancer was 296 082 (6.4% of the total cancers) with the proportion as 27.7/ 100 000, ranking the sixth among all the cancers. 72.8% of the liver cancer cases appeared in men and the sex ratio of male to female was 2.7:1. In terms of deaths due to liver cancer, 74.3% of them occurred in men, with sex ratio of male to female as 2.9:1. At any age group, the incidence and mortality of liver cancer among males were higher than those of females. Liver cancer happened more frequently among people older than 40 years of age, particularly among males. Data under our prediction showed that the incidence and mortality of liver cancer in China would gradually increase in the next 20 years.
Conclusion: Liver cancer is one of the most important public health issues in China. Both incidence and mortality of liver cancer have been increasing in China. The key populations for liver cancer prevention and control programs should be those who were older than 40-year-old, particularly on men.
Download full-text PDF |
Source |
---|
Background & Aims: This systematic literature review of qualitative findings aims to identify the perceived barriers and enablers for hepatocellular carcinoma (HCC) surveillance from patient and clinician perspectives.
Methods: A systematic search of databases using key term combinations with the following inclusion criteria: 1) qualitative and quantitative (survey) studies exploring barriers and enablers of HCC surveillance, and 2) qualitative and quantitative (survey) studies exploring barriers and enablers of enagagement in clinical care for patients with cirrhosis and/or viral hepatitis.
Results: The search returned 445 citations: 371 did not meet the study criteria and were excluded.
Medicine (Baltimore)
January 2025
Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Rationale: Peliosis hepatis (PH) is a rare disease with few clinical reports and complex etiology. However, there have been no reports of hyperprolactinemia (HPRL) leading to PH at present. This paper, through case reports, expands the understanding of the etiology of PH and the pathological damage effect of prolactin (PRL).
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of General Surgery, Nujiang Prefecture People's Hospital, Yunnan, Nujiang, China.
Rationale: Peritoneal mucinous cystadenoma is rare in the clinic, lacks specific clinical manifestations, tumor markers, and imaging features, and is easily misdiagnosed and missed. Clinical practitioners should maintain a high level of vigilance. Here, we report a case of laparoscopic peritoneal mucinous cystadenoma stripping to improve our understanding of the disease.
View Article and Find Full Text PDFMedicine (Baltimore)
January 2025
Department of General Surgery, The Second Hospital of Hebei Medical University, Shijiazhuang City, Hebei Province, China.
Colorectal cancer is one of the most common malignant tumors in the world, and about 50% of its advanced patients will have liver metastasis. Preoperative assessment of the risk of liver metastasis in patients with colorectal cancer is of great significance for making individualized treatment plans. Traditional imaging examinations and tumor markers have some limitations in predicting the risk of liver metastasis.
View Article and Find Full Text PDFJ Chin Med Assoc
November 2024
School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan, ROC.
Background: Few studies have explored the genetic changes and clinicopathological features of stage II/III gastric cancer (GC) patients with no tumor recurrence, early recurrence, or late recurrence after curative surgery.
Methods: In this study, 376 patients who underwent curative surgery for stage II/III GC were analyzed. The clinical and genetic features of patients with no recurrence, early recurrence (<2 years), and late recurrence (≥2 years) were compared.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!